Bactericidal antibiotics alter microbial metabolism as part of their lethality and can damage mitochondria in mammalian cells. In addition, antibiotic susceptibility is sensitive to extracellular metabolites, but it remains unknown whether metabolites present at an infection site can affect either treatment efficacy or immune function. Here, we quantify local metabolic changes in the host microenvironment following antibiotic treatment for a peritoneal Escherichia coli infection. Antibiotic treatment elicits microbiome-independent changes in local metabolites, but not those distal to the infection site, by acting directly on host cells. The metabolites induced during treatment, such as AMP, reduce antibiotic efficacy and enhance phagocytic killing. Moreover, antibiotic treatment impairs immune function by inhibiting respiratory activity in immune cells. Collectively, these results highlight the immunomodulatory potential of antibiotics and reveal the local metabolic microenvironment to be an important determinant of infection resolution.
In Brief
Antibiotic susceptibility is sensitive to metabolites, but how this affects in vivo treatment efficacy remains unexplored. Yang, Bhargava et al. characterize antibiotic-induced changes to the metabolic environment during infection and find that direct actions of antibiotics on host cells induce metabolites that impair drug efficacy and enhance phagocytic activity.
INTRODUCTION
Although the mechanisms of action for most conventional antibiotics have been well studied (Kohanski et al., 2010) , the effects of antibiotic treatment on human physiology and host-microbe interactions are only beginning to be understood (Willing et al., 2011) . Antibiotics have been observed to alter immune responses (Anuforom et al., 2015) , and there is growing appreciation that non-specific actions by antibiotics may promote dis-ease by creating favorable niches for opportunistic pathogens (Theriot et al., 2014) . In light of the pressing challenges of antibiotic resistance and the diminishing drug discovery pipeline (Brown and Wright, 2016) , there is an urgent need to better understand the complex consequences of antibiotic treatment during infection.
We have previously shown that bacterial metabolism participates in the efficacy of bactericidal antibiotics Dwyer et al., 2014; Lobritz et al., 2015) and that antibiotic susceptibility is sensitive to extracellular metabolites (Allison et al., 2011; Meylan et al., 2017) . During infection, bacterial pathogens dynamically remodel their metabolic environment by inducing host catabolism, disrupting metabolic balance, and altering the abundance of energy metabolites, amino acids, and lipids (Beisel, 1975; Dong et al., 2012) . However, it remains unknown how local changes to the metabolic microenvironment might also alter antibiotic efficacy during treatment.
Here, we sought to determine whether antibiotic treatment alters the host metabolic microenvironment and whether such changes alter antibiotic susceptibility or immune function. We performed targeted metabolomics on samples from mice receiving oral antibiotics for a peritoneal infection and found that antibiotic treatment systemically alters metabolites in the host, depleting central metabolism intermediates in the peritoneum. We show that these changes are microbiome independent as they also occur in germ-free (GF) mice. Additionally, we demonstrate that metabolites altered by antibiotic treatment during infection may inhibit antibiotic efficacy and potentiate the phagocytic activity of immune cells. Moreover, we show that antibiotics directly inhibit respiratory activity in immune cells and can consequently impair their phagocytic activity. Together, these results indicate that antibiotic-induced changes to host metabolites and metabolic processes can significantly affect both treatment efficacy and immune function. 
RESULTS

Antibiotic Treatment Depletes Central Metabolism Intermediates in the Peritoneum
To determine whether antibiotics alter metabolites in the host environment, we quantified metabolites in samples from mice receiving antibiotic treatment, bacterial infection, or their combination. We subjected a cohort of 8-week-old C57BL/6J mice to a set of perturbations including antibiotic treatment with 100 mg/mL ciprofloxacin (cipro) delivered in the drinking water (ABX), intraperitoneal infection by Escherichia coli ATCC25922 (INF), or their combination (COMB) ( Figure 1A ). After 24 hr, mice were euthanized and samples from three tissues were collected for metabolomic profiling: (1) the peritoneum, to characterize changes in metabolites local to infection; (2) plasma, to characterize global changes in circulating metabolites; and (3) the lung, to characterize changes in metabolites distal to infection. We performed targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) on these samples (McCloskey et al., 2015) , enabling absolute quantification for nearly 80 metabolites supporting bacterial growth, including amino acids, nucleotides, and central metabolism intermediates (Table S1 ).
Hierarchical clustering of these measurements revealed that the metabolomic profiles clustered first by tissue, then by perturbation ( Figure 1B) , indicating that the metabolic changes elicited by antibiotic treatment or infection were local and tissue specific. Unsupervised principal component analysis (PCA) revealed that antibiotic treatment systemically altered metabolites in the host environment as samples from ABX mice clustered away from control (CTL) samples in all three tissues (Figures 1C, S1A, and S1B). In contrast, infection only exerted local changes, eliciting significant changes in metabolites in the peritoneum ( Figure 1C ), but not in the plasma (Figure S1A) or lung ( Figure S1B ).
To better understand the antibiotic-induced changes in the infection microenvironment, we performed multivariate analysis on the peritoneal samples to identify a metabolite signature corresponding to antibiotic treatment. We applied elastic net regularization and partial least-squares discriminant analysis (PLS-DA) and identified a feature set of metabolites that could discriminate the ABX samples from the union of CTL and INF samples (Ballabio and Consonni, 2013) . This yielded 14 metabolites sufficient for explaining 71% of the variance in metabolites and 40% of the variance in treatments with 100% calibration accuracy and 100% cross-validation accuracy ( Figure 1D ). PLS-DA predicted that antibiotic-associated metabolic changes were most strongly characterized by depletion in uridine diphosphate (udp), glucose-6-phosphate (g6p), and ribulose-5-phosphate (ru5p) ( Figure 1E ). By inspection, many of these metabolites are intermediates in the pentose phosphate pathway, glycolysis, and fatty acid biosynthesis. We performed metabolite set enrichment analysis (MSEA) on these metabolites and found enrichment for ''carbohydrate biosynthesis'' (p = 6.47eÀ4) (Table S2) .
Performing a similar analysis on the plasma and lung samples, we found different metabolite signatures associated with each tissue (Figures S1C and S1D). While MSEA identified lung metabolites as enriched for ''generation of precursor metabolites and energy'' (p = 3.46eÀ3) (Table S3 ), plasma metabolites were not specifically enriched for any metabolic pathways with false discovery rate (FDR)-corrected p values below significance (p = 0.05). We metabolomically profiled additional mice treated with a higher concentration of cipro ( Figure S2A ) and found that 400 mg/mL cipro mostly amplified the antibiotic-induced changes to host metabolites that we had observed at 100 mg/mL cipro in the peritoneum (Figures S2B and S2C ) and plasma ( Figures S2B and S2D) , indicated by a further projection along the first principal component. Together, these data indicate that antibiotic treatment exerts tissue-specific changes in metabolites in the host environment.
Antibiotic Treatment Elicits Microbiome-Independent Changes in Host Metabolites
Antibiotics are thought to systemically alter metabolites in the host environment by acting on the gut microbiome (Reijnders et al., 2016) , but the tissue-specific changes we observed suggested that antibiotics may instead act locally and directly on host cells. To test this hypothesis, we profiled metabolites from GF mice treated with 100 mg/mL cipro delivered in the drinking water ( Figure 2A) . Surprisingly, we found that many of the tissue-specific changes in metabolites from the conventional (CONV) mice also occurred in the GF mice lacking a microbiome ( Figure 2B ).
To better understand whether the antibiotic-induced changes to local metabolites in the CONV mice were due to direct effects on host cells versus effects on the microbiome, we performed PCA on CTL and ABX samples from both the CONV and GF mice for each tissue. PCA orthogonally clustered the peritoneal samples into four distinct quadrants along two principal components that captured 74% of the variance and appeared to directly correspond to presence of either a microbiome (PC 1) or antibiotic treatment (PC 2) ( Figure 2C ). Moreover, inspection of metabolites with the greatest PLS-DA loadings in the peritoneal ABX signature revealed similar fold changes in both CONV and GF mice, despite differences in the untreated CTL concentrations. PCA on the plasma samples similarly revealed that 83% of the variance in plasma metabolites could be explained by direct effects on host cells instead of effects on the microbiome ( Figure 2D ). In contrast, the lung samples did not separate as cleanly along principal components corresponding to a microbiome and antibiotic treatment ( Figure S3 ). Together, these data indicate that most of the antibiotic-induced changes in metabolites are microbiome independent and likely due to direct actions of antibiotics on local host cells.
Antibiotic Treatment Elicits Unique Metabolic Changes in the Presence of Infection
Because antibiotics are administered to treat infection, we sought to characterize metabolic changes that occur in the presence of infection. We first identified an infection-specific metabolic signature by multivariate analysis and then tested whether the complex changes observed under combination treatment could be explained by the ABX and INF signatures. We performed elastic net regularization and used PLS-DA to discriminate the INF samples from the union of CTL and ABX samples, identifying a feature set of nine metabolites sufficient for explaining 90% of the variance in metabolites and 44% of the variance in treatments with 100% calibration accuracy and 100% cross-validation accuracy ( Figure 3A ). These were most strongly characterized by enrichment in guanosine monophosphate (gmp) and depletion in adenosine (adn) and AMP (amp) ( Figure 3B ). MSEA revealed that these were specifically enriched for purine metabolic pathways, including terms such as ''purine nucleotide degradation'' (p = 1.42eÀ6) and ''purine nucleotide biosynthesis'' (p = 1.96eÀ6) (Table S4 ). Because purine metabolites can function as important immune signaling molecules (Cekic and Linden, 2016) , these data suggest that the INF metabolite signature indicated a local induction of host immunity.
PLS-DA of the peritoneal samples from all four treatment groups onto the union of metabolites from the ABX and INF signatures revealed that antibiotic treatment and infection formed two orthogonal dimensions describing the infection microenvironment with 88% calibration accuracy and 83% cross-validation accuracy ( Figure 3C ), in close agreement with the unsupervised PCA of these samples (Figure 1C) . This was supported by the observation that udp, g6p, and ru5p under combination treatment trended similarly to antibiotic treatment, and gmp and adn trended similarly to infection ( Figure 3B ). Collectively, these results suggest that most of the local changes in host metabolites associated with antibiotic treatment of infection could be explained by the independent actions of either antibiotic treatment or infection.
Interestingly, not all of the metabolite changes in the COMB samples could be explained by the independent actions of Figure 3B ). We subjected additional mice to both infection and antibiotic treatment and sampled the peritoneum at earlier time points. We found that amp concentrations peaked at $3-fold 6 hr after infection ( Figure S4 ). COMB samples also scored higher than the ABX samples on the antibiotic axis (LV 2), suggesting that infection may potentiate the metabolic changes elicited by antibiotic treatment ( Figure 3C ). To test this, we performed elastic net regularization and used PLS-DA to identify a COMB-specific metabolite signature discriminating the COMB samples from the union of CTL, ABX, and INF samples. This comprised 20 metabolites sufficient for explaining 55% of the variance in metabolites and 35% of the variance in treatments with 100% calibration accuracy and 96% cross-validation accuracy ( Figure 3D ). PLS-DA predicted that this signature was enriched for thymine (thym) and amp, and depleted in 3-phospho-D-glyceroyl phosphate (23dpg) and guanosine (gsn) (Figures 3E and 3B) . MSEA revealed these to be enriched in diverse metabolic processes, including various nucleotide, energy, and amino acid metabolism pathways (Table S5) .
Metabolites Altered by Antibiotic Treatment during Infection Inhibit Drug Efficacy
Antibiotic efficacy is sensitive to the abundance of extracellular metabolites (Allison et al., 2011; Meylan et al., 2017) . We hypothesized that host metabolites induced by antibiotic treatment of infection might feed back on drug susceptibility in the pathogen. To test this hypothesis, we quantified the minimum inhibitory concentration (MIC) of cipro in E. coli cells following 10 mM supplementation with thym or amp, which was $13 ng/mL without supplementation. While thym supplementation did not appear to alter the MIC ($13.5 ng/mL), amp supplementation significantly decreased cipro susceptibility, increasing the MIC to $100 ng/mL ( Figure 4A ). Time-kill experiments with 25 ng/mL cipro revealed that amp supplementation elicited dose-dependent protection ( Figure 4B) .
We further characterized changes in MIC promoted by supplementation with metabolites from the COMB, ABX, or INF signatures and found that many of these metabolites also inhibited drug susceptibility (Figures 4A, 4C, and 4D ). MSEA on these metabolites identified ''amines and polyamines biosynthesis'' as the metabolic pathway most enriched by these metabolites (p = 3.99eÀ4) (Table S6 ). Together, these results demonstrate that host metabolites induced by antibiotics during treatment of infection can feed back and affect antibiotic efficacy.
Direct Actions of Antibiotic Treatment on Immune Cells Inhibit Phagocytic Killing
Bactericidal antibiotics can impair mitochondrial function in epithelial cells and inhibit their respiratory activity (Kalghatgi et al., 2013) . In addition, metabolites present in the host microenvironment may initiate signaling cascades in immune cells that lead to metabolic reprogramming and functional changes (O'Neill and Hardie, 2013) . Because efficient phagocytosis involves induction of a highly energy-dependent respiratory burst (Murphy and Weaver, 2016) , we sought to determine whether antibiotic treatment might also interfere with the respiratory activity of immune cells. We pre-treated mouse macrophages with cipro and measured changes in oxygen consumption following electron transport chain uncoupling ( Figure 5A) . These data revealed a dose-dependent inhibition of respiratory capacity ( Figure 5B ).
We hypothesized that antibiotic-induced impairments in respiration and/or the induction of local metabolites might physiologically alter the phagocytic activity of immune cells recruited to a site of infection. To test this hypothesis, we enumerated E. coli cells attached or killed by macrophages following treatment with cipro and/or amp. Compared with untreated cells, macrophages pre-treated with 20 mg/mL cipro for 3 hr (ABX) engulfed fewer E. coli cells (Figures 5C and S5A) and possessed more surviving cells following lysis of the macrophages (Figures 5D and  S5B) , indicating a significant decrease in the killing of engulfed cells ( Figure 5E ). In contrast, we found that 10 mM amp significantly increased pathogen engulfment (Figures 5C and S5C ) and decreased pathogen survival ( Figures 5D and S5D) , indicating that metabolites induced at the site of infection by antibiotics may feed forward and potentiate immune function. Interestingly, antibiotic treatment exerted a dominant-negative effect over the metabolic potentiation in macrophages subjected to both cipro and amp (ABX + amp), most prominently in the ability to engulf pathogens. Collectively, these results indicate that antibiotic treatment can directly act on immune cells and metabolically impair their function.
DISCUSSION
Infections are complex host-microbe interfaces composed of multiple species, cell types, and biochemical species. While local metabolism is understood to be important for pathogens to establish their niche, the contribution of antibiotics to this environment is poorly understood. Here, we investigated the effects of antibiotic treatment on host metabolism in a commonly used and well-defined model of in vivo infection. While antibiotics normally act in concert with host immune cells to remove pathogens at a site of infection, we report that antibiotics also act synergistically with pathogen cells to remodel the local metabolic environment ( Figure 6 ). We demonstrate that metabolites induced in this environment have the capacity to affect both antibiotic efficacy and immune function and that the direct consequences of antibiotics on the metabolism of immune cells can inhibit their phagocytic activity. These data highlight the complex interactions elicited by antibiotics at the site of infection and support prior in vitro studies demonstrating that the host metabolic environment is critical for the function of both antibiotics (Yang et al., 2017) and immune cells (Buck et al., 2017) .
Antibiotics are thought to systemically alter metabolites in the host by manipulating gut microbiome taxonomy (Reijnders et al., 2016) . We report that orally administered antibiotics also induce dose-dependent and microbiome-independent changes in metabolites in the host environment. Of significance, we find that most of the metabolic variation observed in conventionally raised mice also appeared in GF mice in both the plasma and peritoneum. These results are consistent with our previous observations that bactericidal antibiotics directly induce mitochondrial dysfunction in mammalian cells (Kalghatgi et al., 2013) and our present observations that antibiotics can inhibit the phagocytic activity of immune cells, which require a functioning respiratory chain for their bactericidal oxidative burst. In our in vitro experiments, these effects appeared to occur at concentrations R1 mg/mL, well within the pharmacokinetic range of 1-5 mg/mL achieved in human serum following oral delivery and R10 mg/mL in other tissues following intravenous delivery (Vance-Bryan et al., 1990) .
Nutrient availability at a site of infection is an important regulator of antibiotic susceptibility (Amato et al., 2014) , and previous studies have demonstrated that antibiotic tolerance may be overcome metabolically by stimulating bacterial central metabolism (Allison et al., 2011; Meylan et al., 2017) . We report that diverse metabolites induced by antibiotics at the site of infection also have the potential to alter both antibiotic efficacy and immune function. An example of this is in the synergistic and local induction of amp, an energy currency precursor and a participant in purine metabolism that exerts immunomodulation through AMP-activated protein kinase (O'Neill and Hardie, 2013) . We find that amp alters E. coli sensitivity to cipro and enhances phagocytic killing by macrophages. Although the amp concentrations that we measured from our bulk lavage of the peritoneum ($10-50 mM) did not exceed the R100 mM required to elicit an effect on either antibiotic efficacy or immune function, it is possible that amp concentrations were higher in regional peritoneal microdomains due to the large surface area and complex geometry of the peritoneum. Moreover, amp concentrations are generally $200 mM in mammalian tissues (Traut, 1994) and can increase >100-fold in human tissues following metabolically demanding activities such as exercise (Harkness et al., 1983) . Amp therefore may have more significant effects in other tissues or other in vivo infection models.
While here we use amp to exemplify a single form of complex metabolic crosstalk between host and microbe physiology in the context of infection, other metabolites altered at a site of infection likely also significantly affect antibiotic efficacy or immune function through undiscovered mechanisms. MSEA identified polyamine biosynthesis as a metabolic process enriched by the protective metabolites from our metabolite screens. Interestingly, several studies demonstrate that polyamines can protect pathogens against antibiotic treatment (Kwon and Lu, 2006) by inhibiting drug uptake (Sarathy et al., 2013) , inducing protective stress responses (Tkachenko et al., 2006) , and reducing antibiotic-induced reactive oxygen species (Tkachenko et al., 2012) . Future studies will need to clarify the mechanisms by which diverse metabolites may alter antibiotic efficacy (Yang et al., 2017) .
Finally, our work identifies the local metabolic microenvironment as an important determinant in the resolution of infection, due to its actions on antibiotic susceptibility and immune function. It is likely that interpersonal differences in the combination of such metabolites may contribute to variable treatment outcomes across patients suffering from similar infections (Lee and Collins, 2011) . Additionally, dynamic changes to these environments, for instance by prophylactics, may be useful for maximizing both antibiotic efficacy and immune function. As recognition of metabolic context dependence for antibiotic efficacy is growing for important human pathogens (Black et al., 2014) , our findings support the use of metabolic adjuvants to enhance our existing antibiotic arsenal (Wright, 2016) .
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